Vivos Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 2, 2021, covering events occurring on March 29 and March 30, 2021. Vivos Therapeutics, Inc. (VVOS), an emerging growth company, operates in the medical device sector, specifically focusing on obstructive sleep apnea treatments via the Vivos System.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for a reporting period. This document reports a specific corporate event rather than periodic financial results.
Material Changes and Corporate Actions
- New Service Launch: The Company launched "MyoCorrect," a telemedicine service providing orofacial myofunctional therapy (OMT) to dentists enrolled in the Vivos Integrated Practice (VIP) program.
- Asset Acquisition: On March 29, 2021, Vivos acquired certain assets from MyoCorrect, LLC and entered into related agreements to facilitate the service.
- Cost Structure: The new service aims to reduce costs for VIPs, offering OMT at an initial price point of $1,000 - $1,200, compared to the typical $1,600 - $2,500 cost for independent providers.
- Compensation Arrangements:
- A VIP dentist and a certified OMT therapist are entitled to fees per MyoCorrect case, subject to an aggregate cap.
- The Company issued warrants to the OMT therapist to purchase 200,000 shares of common stock at an exercise price of $7.50 per share.
- 25,000 warrants vested immediately; the remainder vest based on pre-determined performance metrics regarding MyoCorrect utilization.
Guidance, Outlook, and Risks
Management commentary indicates that incorporating OMT into treatment protocols has led to reported improvements in case acceptance, patient compliance, treatment times, and clinical outcomes. The filing does not contain specific forward-looking financial guidance, risk factors, or contingencies beyond the operational details of the new service launch.
Investor Verification Checklist
- Verify the terms of the asset acquisition agreement with MyoCorrect, LLC.
- Review the specific performance metrics required for the vesting of the 175,000 unvested warrants issued to the OMT therapist.
- Assess the aggregate cap on fees payable to the VIP dentist and OMT therapist.
- Monitor the adoption rate of the MyoCorrect service within the existing VIP network.